NCT04648241View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

February 21, 2022

Study Completion Date

February 21, 2022

Conditions
Tick-Borne Encephalitis
Interventions
BIOLOGICAL

TBE vaccine 0.5 mL

TBE vaccine 0.5 mL (intramuscular injection).

BIOLOGICAL

TBE vaccine 0.25 mL

TBE vaccine 0.25 mL (intramuscular injection).

Trial Locations (6)

812-0025

Medical Co. LTA PS Clinic, Fukuoka

069-0816

Azuma kodomo katei clinic, Ebetsu Shi

006-0831

Watanabe Pediatric Allergy Clinic, Sapporo

062-0907

Ohigesenseino Kodomo Clinic, Sapporo

063-0841

SUZURAN Children's Clinic, Sapporo

400-0853

Childrens clinic of Kose, Kofu

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04648241 - Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older | Biotech Hunter | Biotech Hunter